Apoptosis inducer 46 

Apoptosis inducer 46 is an apoptosis inducer. Apoptosis inducer 46 exhibits potent and selective growth inhibitory effects on metastatic triple-negative breast cancer (TNBC) cells. Apoptosis inducer 46 induces G2/M phase cell cycle arrest and apoptotic cell death in MDA-MB-231 cells, and blocks NF-κB nuclear translocation. Apoptosis inducer 46 can be used for the study of TNBC^[1].

Apoptosis inducer 46 (Compound 5d) (96 h) exhibits potent growth inhibitory effects on metastatic triple-negative breast cancer (TNBC) MDA-MB-231, HCC 1806, MCF-7, BEAS 2B cells with IC₅₀s of 0.38 μM, 0.31 μM, 0.39 μM, 0.7 μM, respectively^[1].
Apoptosis inducer 46 (5-40 μM, 2-4 h) significantly reduces proteasome activity in MDA-MB-231 cells with an IC₅₀ of 37.0 μM for proteasome inhibition, and induces accumulation of ubiquitinated proteins^[1].
Apoptosis inducer 46 (5 μM, 24-72 h) increases the apoptosis rate and causes progressive accumulation of MDA-MB-231 cells in the G2/M phase of the cell cycle^[1].
Apoptosis inducer 46 (5-20 μM) stabilizes cyclin D1, p53, and p21 proteins, prevents degradation of IκBα, IκBε, and IκKγ, and inhibits nuclear translocation of NF-κB in MDA-MB-231 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

375.46

C₂₄H₂₅NO₃

3085356-41-5

OC1=C(C=C(C=C1)/C=C2CN(C3CC3)C/C(C\2=O)=C\C4=CC=C(C=C4)C)OC

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Khor PY, et al. Discovery of New Non-Symmetrical Heterocyclic Pentanoid Derivatives Targeting Metastatic Triple-Negative Breast Cancer. Bioorg Med Chem Lett. 2025 Aug 1;123:130232.  [Content Brief]